A normal ECG from six years ago does NOT remain valid today—you need repeat ECG testing based on your current clinical context, not on a fixed schedule.
The decision to repeat an ECG depends entirely on whether you have new risk factors for QT prolongation, not simply on the passage of time. According to the 2023 Canadian Cardiovascular Society guidelines, routine periodic ECG monitoring is not recommended for healthy individuals with previously normal QT intervals 1.
When You DO Need a Repeat ECG
The guidelines are clear that ECG monitoring should be risk-stratified and clinically driven 1. You should obtain a new ECG if any of the following situations arise:
High-Priority Indications for Repeat ECG:
- Starting high-risk QT-prolonging medications (methadone, sotalol, dofetilide) 1
- Adding a second QT-prolonging drug when already taking one (e.g., adding a quinolone antibiotic to an antidepressant) 1
- Development of electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) 1
- New renal impairment (many QT-prolonging drugs accumulate with kidney disease) 1
- Starting diuretics in combination with QT-prolonging medications 1
- Female sex with new medications (women are at higher risk for drug-induced QT prolongation) 1
- Advanced age (elderly patients have higher baseline risk) 1
Medications That Warrant ECG Consideration:
The "anti's" to remember 1:
- Antibiotics: macrolides (especially erythromycin), fluoroquinolones
- Antifungals: triazoles like fluconazole
- Antiarrhythmics: sotalol, dofetilide
- Antipsychotics/Antidepressants: citalopram, escitalopram (higher risk); sertraline, paroxetine (negligible risk)
- Antiemetics: ondansetron
- Analgesics: methadone, triptans
When You DON'T Need Routine Repeat ECGs
If you remain healthy without new medications or medical conditions, there is no evidence-based recommendation for routine periodic ECG screening 1. The guidelines explicitly state that "it is impractical and low-yield to do an ECG on every patient who commences a drug that could possibly prolong the QT interval" 1.
For example, a healthy person starting a low-risk SSRI like sertraline with no other risk factors does not need routine ECG monitoring 1.
Important Caveats
Research shows that ECG abnormalities can develop over time—one study found that 42.8% of healthy volunteers with normal baseline ECGs developed new abnormalities over 6 weeks, though many were transient 2. However, this doesn't justify routine screening in asymptomatic individuals without risk factors.
The QT interval naturally lengthens with age 3, and persistent ischemic ECG changes carry prognostic significance 4, but these findings support targeted screening in high-risk populations rather than universal periodic monitoring.
Practical Algorithm
- Review your current medications using www.crediblemeds.org 1
- If starting any QT-prolonging medication: Get baseline ECG, then repeat after dose changes for high-risk drugs 1
- If taking QT-prolonging medication and developing electrolyte issues or renal impairment: Obtain ECG 1
- If completely healthy with no new medications or conditions: No routine repeat ECG needed
The key principle: ECG monitoring should be triggered by clinical changes, not calendar dates.